Cladribine, Isatuximab
merck,sanofi
[]
two key upfront studies master 2 and midas .from the usa and the ifm alongside the uk radar study . will be great to see the readouts from these studies #eha2022 #hme 
passionate about Haematology, improving outcomes for myeloma patients. Also cycle +live in the most beautiful part of England and the best city in the world ...